Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06
Published : Mar-2012

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Cryptococcal Meningitis Global Clinical Trials Review, H2, 2017

Cryptococcal Meningitis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Cryptococcal Meningitis Global Clinical Trials Review, H2, 2017" provides an overview of Cryptococcal Meningitis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptococcal Meningitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2017

Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2017" provides an overview of Cytomegalovirus (CMV) Retinitis clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (CMV) Retinitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2017

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2017" provides an overview of Coronary Arteriosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Coronary Arteriosclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Cryptococcosis Global Clinical Trials Review, H2, 2017

Cryptococcosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Cryptococcosis Global Clinical Trials Review, H2, 2017" provides an overview of Cryptococcosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptococcosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017" provides an overview of Cytomegalovirus (HHV-5) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated us......
$2500

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2017" provides an overview of Coronary Artery Disease (CAD) (Ischemic Heart Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Coronary Artery Disease (CAD) (Ischemic Heart Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based ......
$2500

Cryptosporidiosis Global Clinical Trials Review, H2, 2017

Cryptosporidiosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Cryptosporidiosis Global Clinical Trials Review, H2, 2017" provides an overview of Cryptosporidiosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptosporidiosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

ForeSights: Digiceuticals

ForeSights: Digiceuticals Summary Digiceuticals are computer software, smartphones, digital services, and so on with the potential to improve health outcomes as much as drugs can. Digiceuticals reside at the intersection of medicine and digital health technology and have the potential to increase medication compliance and enhance focus on patient behavior modification. Digiceuticals are a promising new development in healthcare that use technology to leverage and improve the effectiveness of pharmaceuticals, even replacing them in some cases. Scope - Technology is often used to create pharmaceuticals, but is rarely used to improve the efficacy of drugs already prescribed. The latter is at the core of the digiceuticals concept. - Digiceuticals have the potential to increase medication ......
$495

Cytopenia Global Clinical Trials Review, H2, 2017

Cytopenia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Cytopenia Global Clinical Trials Review, H2, 2017" provides an overview of Cytopenia clinical trials scenario. This report provides top line data relating to the clinical trials on Cytopenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are ......
$2500

Coronary Disease Global Clinical Trials Review, H2, 2017

Coronary Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Coronary Disease Global Clinical Trials Review, H2, 2017" provides an overview of Coronary Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Coronary Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500